$IVVD
Invivyd, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024057017 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $2.264M $0.00 $0.00
YoY Change
Cost Of Revenue $88.00K
YoY Change
Gross Profit $2.176M
YoY Change
Gross Profit Margin 96.11%
Selling, General & Admin $21.09M $14.93M $15.09M
YoY Change 108.66% 35.17% 43.41%
% of Gross Profit 969.16%
Research & Development $30.33M $31.16M $62.27M
YoY Change -30.46% 14.55% 206.42%
% of Gross Profit 1394.03%
Depreciation & Amortization $128.0K $122.0K $120.0K
YoY Change 6.67% 1.67% 300.0%
% of Gross Profit 5.88%
Operating Expenses $51.42M $46.09M $77.35M
YoY Change -4.55% 17.96% 150.82%
Operating Profit -$49.25M -$46.09M
YoY Change -8.59% 17.96%
Interest Expense $2.000M $1.100M $2.700M
YoY Change 25.0% 0.0% -28.95%
% of Operating Profit
Other Income/Expense, Net $2.000M $2.593M $398.0K
YoY Change -45.16% -30.85% -102.27%
Pretax Income -$47.25M -$43.50M -$73.65M
YoY Change -5.94% 23.15% 65.25%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$47.25M -$43.50M -$73.65M
YoY Change -5.93% 23.14% 65.25%
Net Earnings / Revenue -2086.88%
Basic Earnings Per Share -$0.40 -$0.38
Diluted Earnings Per Share -$0.40 -$0.38 -$0.67
COMMON SHARES
Basic Shares Outstanding 119.3M 119.2M 110.1M
Diluted Shares Outstanding 119.4M 115.6M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.9M $189.4M $200.6M
YoY Change -50.45% -43.2% -46.06%
Cash & Equivalents $147.9M $189.4M $200.6M
Short-Term Investments $0.00
Other Short-Term Assets $16.27M $19.51M $23.31M
YoY Change 46.58% 82.35% 417.93%
Inventory $5.333M $109.0K $0.00
Prepaid Expenses
Receivables $2.888M $0.00
Other Receivables $639.0K
Total Short-Term Assets $173.0M $209.9M $224.9M
YoY Change -44.19% -39.1% -40.34%
LONG-TERM ASSETS
Property, Plant & Equipment $1.772M $1.901M $4.125M
YoY Change -16.53% -15.59% 80.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.781M $1.857M $175.0K
YoY Change 512.03% 538.14% -8.38%
Total Long-Term Assets $4.335M $5.585M $4.300M
YoY Change -20.14% -5.99% -31.2%
TOTAL ASSETS
Total Short-Term Assets $173.0M $209.9M $224.9M
Total Long-Term Assets $4.335M $5.585M $4.300M
Total Assets $177.3M $215.5M $229.2M
YoY Change -43.77% -38.54% -40.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.499M $1.168M $7.953M
YoY Change 82.37% -80.25% 424.26%
Accrued Expenses $26.82M $34.00M $42.30M
YoY Change 0.29% 134.49% 93.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.70M $36.35M $50.29M
YoY Change 12.92% 64.78% 100.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $1.422M
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $1.422M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.70M $36.35M $50.29M
Total Long-Term Liabilities $0.00 $0.00 $1.422M
Total Liabilities $36.70M $36.97M $51.71M
YoY Change 8.43% 55.24% 90.14%
SHAREHOLDERS EQUITY
Retained Earnings -$822.8M -$775.6M -$732.1M
YoY Change 32.92% 36.38% 37.25%
Common Stock $963.5M $954.1M $909.6M
YoY Change 6.99% 6.53% 2.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $140.6M $178.5M $177.5M
YoY Change
Total Liabilities & Shareholders Equity $177.3M $215.5M $229.2M
YoY Change -43.77% -38.54% -40.19%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$47.25M -$43.50M -$73.65M
YoY Change -5.93% 23.14% 65.25%
Depreciation, Depletion And Amortization $128.0K $122.0K $120.0K
YoY Change 6.67% 1.67% 300.0%
Cash From Operating Activities -$41.60M -$50.21M -$59.24M
YoY Change 11.26% 21.93% 24.96%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $140.0K -$5.000K
YoY Change -77.56% -100.41%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $77.92M
YoY Change -100.0% -100.0% -156.63%
Cash From Investing Activities $0.00 -$140.0K $77.91M
YoY Change -100.0% -100.19% -156.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 92.00K 39.10M 145.0K
YoY Change -65.93% 7114.21% 3.57%
NET CHANGE
Cash From Operating Activities -41.60M -50.21M -59.24M
Cash From Investing Activities 0.000 -140.0K 77.91M
Cash From Financing Activities 92.00K 39.10M 145.0K
Net Change In Cash -41.51M -11.25M 18.82M
YoY Change 816.27% -132.72% -110.11%
FREE CASH FLOW
Cash From Operating Activities -$41.60M -$50.21M -$59.24M
Capital Expenditures $0.00 $140.0K -$5.000K
Free Cash Flow -$41.60M -$50.35M -$59.24M
YoY Change 11.26% 20.45% 21.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001832038
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40703
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
INVIVYD, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1403134
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1601 Trapelo Road
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 178
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2024Q1 dei City Area Code
CityAreaCode
781
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
819-0080
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
IVVD
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119315787
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189388000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200641000
CY2024Q1 us-gaap Inventory Net
InventoryNet
109000
CY2023Q4 us-gaap Inventory Net
InventoryNet
0
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20386000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24240000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
209883000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
224881000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1901000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1896000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1827000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2229000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1857000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175000
CY2024Q1 us-gaap Assets
Assets
215468000
CY2023Q4 us-gaap Assets
Assets
229181000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1168000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7953000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34003000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40860000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1134000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1443000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
40000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
35000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
36345000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50291000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
625000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
722000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
700000
CY2024Q1 us-gaap Liabilities
Liabilities
36970000
CY2023Q4 us-gaap Liabilities
Liabilities
51713000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119221230
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119221230
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110160684
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110160684
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
954063000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
909539000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-775565000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-732069000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
178498000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
177468000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
215468000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229181000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31160000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27201000
CY2024Q1 ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
CY2023Q1 ivvd Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
825000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14929000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11045000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
46089000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
39071000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46089000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-39071000
CY2024Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
2593000
CY2023Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
3750000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2593000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3750000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-43496000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35321000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
157000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43495000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35164000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115618209
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115618209
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108785519
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108785519
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
355970000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q1 ivvd Exercise Of Stock Options
ExerciseOfStockOptions
459000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5400000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
83000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
157000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35321000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
326749000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
177468000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5379000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39057000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
89000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-43496000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
178498000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-43496000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-35321000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5379000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5400000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2543000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
402000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
379000
CY2024Q1 us-gaap Depreciation
Depreciation
122000
CY2023Q1 us-gaap Depreciation
Depreciation
120000
CY2024Q1 ivvd Quarterly Fee
QuarterlyFee
600000
CY2024Q1 ivvd Delivery Fee
DeliveryFee
200000
CY2024Q1 ivvd Completion Fee
CompletionFee
200000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
104000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4015000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6269000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1682000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
100000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6785000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4430000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6964000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6909000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-406000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-381000
CY2024Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
13000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-700000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50214000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41181000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
75660000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
140000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
624000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-140000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
75036000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
459000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
89000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83000
CY2024Q1 ivvd Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
39285000
CY2023Q1 ivvd Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
0
CY2024Q1 ivvd Payments For Offering Costs
PaymentsForOfferingCosts
273000
CY2023Q1 ivvd Payments For Offering Costs
PaymentsForOfferingCosts
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39101000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
542000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11253000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34397000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200641000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92076000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189388000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126473000
CY2024Q1 ivvd Deferred Offering And Issuance Cost Included In Accrued Expenses
DeferredOfferingAndIssuanceCostIncludedInAccruedExpenses
133000
CY2023Q1 ivvd Deferred Offering And Issuance Cost Included In Accrued Expenses
DeferredOfferingAndIssuanceCostIncludedInAccruedExpenses
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-43500000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-775600000
CY2024Q1 ivvd Exercise Fee
ExerciseFee
1000000
CY2022Q3 ivvd Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
3000000
CY2020Q4 ivvd Accrued Upfront Fee
AccruedUpfrontFee
200000
CY2024Q1 ivvd Royalty Based On Net Sales Of Licensed Products Percentage
RoyaltyBasedOnNetSalesOfLicensedProductsPercentage
0.01
CY2024Q1 us-gaap Royalty Expense
RoyaltyExpense
0
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p>
CY2024Q1 ivvd Annual Gross Revenue
AnnualGrossRevenue
1235000000
CY2024Q1 us-gaap Convertible Debt
ConvertibleDebt
1000000000
CY2024Q1 ivvd Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2023Q1 ivvd Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2024Q1 ivvd Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
15582000
CY2023Q4 ivvd Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
19962000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1141000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1770000
CY2024Q1 ivvd Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
2788000
CY2023Q4 ivvd Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1575000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
875000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
933000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20386000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24240000
CY2024Q1 ivvd Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
29139000
CY2023Q4 ivvd Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
28151000
CY2024Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
3008000
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1732000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1689000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
10752000
CY2024Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
167000
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
225000
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
34003000
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
40860000
CY2024Q1 ivvd Quarterly Fee
QuarterlyFee
1300000
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.48
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6824712
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q3 ivvd Lessee Operating Lease Total Lease Space
LesseeOperatingLeaseTotalLeaseSpace
9600
CY2021Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
400000
CY2022Q2 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
700000
CY2022Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
1300000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
430000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
430000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
3000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
12000
CY2024Q1 us-gaap Lease Cost
LeaseCost
433000
CY2023Q1 us-gaap Lease Cost
LeaseCost
442000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
435000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
432000
CY2024Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
1087000
CY2024Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
430000
CY2024Q1 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
328000
CY2024Q1 us-gaap Purchase Obligation
PurchaseObligation
1845000
CY2024Q1 ivvd Present Value Adjustment
PresentValueAdjustment
-86000
CY2024Q1 ivvd Present Value Of Operating Lease Liability
PresentValueOfOperatingLeaseLiability
1759000
CY2024Q1 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.06
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2023Q1 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.06
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1100000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
600000
CY2022Q4 ivvd Cash Fees
CashFees
3000000
CY2024Q1 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
46292290
CY2022Q3 us-gaap Partners Capital Account Public Sale Of Units Net Of Offering Costs
PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts
400000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23065514
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.08
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24745000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3647000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.22
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
348481
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.05
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26364033
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.95
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33249000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
26364033
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.95
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
33249000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9143369
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.79
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9256000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.53
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.34
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5379000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5400000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
40200000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2020Q3 ivvd Percentage Of Total Number Of Shares Of Common Stock Outstanding
PercentageOfTotalNumberOfSharesOfCommonStockOutstanding
0.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2685546
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-43496000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35321000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115618209
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115618209
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108785519
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108785519
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33188745
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30801970

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
ivvd-20240331_htm.xml Edgar Link completed
0000950170-24-057017-index-headers.html Edgar Link pending
0000950170-24-057017-index.html Edgar Link pending
0000950170-24-057017.txt Edgar Link pending
0000950170-24-057017-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ivvd-20240331.htm Edgar Link pending
ivvd-20240331.xsd Edgar Link pending
ivvd-ex31_1.htm Edgar Link pending
ivvd-ex31_2.htm Edgar Link pending
ivvd-ex32_1.htm Edgar Link pending
ivvd-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending